Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$50.03 USD
-0.26 (-0.52%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $50.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 321 - 338 ( 338 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Full Speed Ahead into 2016 - Ultragenyx Analyst Day
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Ultragenyx Reports 3Q15 and Updates Progress on All Fronts; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LC-FAOD Data Lays out Path(s) to Pivotal Development
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
LC-FAOD Data Lays out Path(s) to Pivotal Development
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Infant Data Support Role for Triheptanoin in LC-FAOD Ahead of Phase II Data Later this Year; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Ultragenyx Reports 2Q15 Ahead of a Busy 2H15; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
KRN23 Improves Rickets in Pediatric XLH - Reiterate OUTPERFORM and Raising PT to $122
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Plenty of Clinical and Regulatory Catalysts Ahead for Ultragenyx; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
De-risking Data and Potential Faster Path to Market for KRN23; Reiterate OUTPERFORM and Raising PT to $102
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 25th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Physicians Weigh in on XLH Ahead of KRN23 Data this Quarter
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 11th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Triheptanoin Improves GLUT1-DS Symptoms in Investigator-led Study
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 6th
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM and $74 PT; Building for the Long Haul
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H